申请人:——
公开号:US20020115688A1
公开(公告)日:2002-08-22
Disclosed is a method for identifying compounds that bind to or modulate a glutamate transporter. The disclosed method is useful for identifying compounds that can inhibit, stimulate, or modulate the activity of the glutamate transporter and thus affect glutamate reuptake. The method is a screening technique where compounds known to bind to glutamate receptors (for example, glutamate receptor ligands, including many agonists, and antagonists) are bound to a glutamate transporter and compounds are screened to identify those that can alter the binding of the glutamate receptor-binding compounds. Compounds shown to alter the binding of the receptor compounds from glutamate transporters in the disclosed assay can have a variety of effects on glutamate transporter activity including activation or inhibition. These compounds are expected to affect or interfere with glutamate reuptake by the glutamate transporter and thus can be used to modulate, stimulate, or inhibit glutamate reuptake. Such compounds are useful to treat various neurological diseases and conditions involving glutamate transporter and glutamate receptor activation. One of the compounds is (2S,4R)-4-methylglutamate or [
3
H]-(2S,4R)-4-methylglutamate. For example, excess extracellular glutamate is a cause of excessive activation of glutamate receptors. Stimulating glutamate reuptake by glutamate transporters can ameliorate excessive activation of glutamate receptors by reducing the extracellular glutamate concentration. Prodrug forms of transporter compounds are preferred for use as drugs.
本文揭示了一种识别结合或调节谷氨酸转运体的化合物的方法。揭示的方法用于识别可以抑制、刺激或调节谷氨酸转运体活性的化合物,从而影响谷氨酸的再摄取。该方法是一种筛选技术,其中已知与谷氨酸受体结合的化合物(例如,谷氨酸受体配体,包括许多激动剂和拮抗剂)与谷氨酸转运体结合,并筛选化合物以识别可以改变谷氨酸受体结合化合物的结合的化合物。在揭示的测定中,被证明可以改变受体化合物从谷氨酸转运体中结合的化合物可以对谷氨酸转运体活性产生各种效应,包括激活或抑制。这些化合物预计会影响或干扰谷氨酸转运体的谷氨酸再摄取,从而可以用于调节、刺激或抑制谷氨酸再摄取。这些化合物对于治疗涉及谷氨酸转运体和谷氨酸受体激活的各种神经疾病和病症非常有用。其中一种化合物是(2S,4R)-4-甲基谷氨酸或[3H] -(2S,4R)-4-甲基谷氨酸。例如,过多的细胞外谷氨酸是谷氨酸受体过度激活的原因。通过刺激谷氨酸转运体的谷氨酸再摄取,可以通过降低细胞外谷氨酸浓度来缓解谷氨酸受体的过度激活。药物使用时,转运体化合物的前药形式更受欢迎。